Pfizer Inc (PFE) 34.77 $PFE MEDIVATION SHAREHOL
Post# of 273249
Posted On: 09/07/2016 5:10:03 AM
Pfizer Inc (PFE) 34.77 $PFE
MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Medivation, Inc. (MDVN) Over the Proposed Sale of the Company to Pfizer Inc.
PR Newswire - Tue Sep 06, 3:49PM CDT
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medivation, Inc. ("Medivation" or the "Company"
(NasdaqGS:MDVN) for potential breaches of fiduciary duties in connection with the sale of the Company to Pfizer Inc. for approximately $14 billion.
MDVN: 80.84 (-0.01), PFE: 34.77 (unch)
Watch for Shares of Pfizer (PFE) to Approach Resistance at $34.97
Comtex SmarTrend(R) - Tue Sep 06, 9:08AM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $34.74 today and have reached the first resistance level of $34.87. Investors may be interested in a cross of the next upside pivot targets of $34.97 and $35.20.
PFE: 34.77 (unch)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Morgan Stanley Global Healthcare Conference
BusinessWire - Tue Sep 06, 9:00AM CDT
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 3:30 p.m. Eastern Daylight Time.
PFE: 34.77 (unch), MS: 31.75 (-0.14)
Pharmaceutical Products and CMO Market is Expanding at a CAGR 11.6% by 2024; Improving Regulatory Scenario Across Latin America Market: Transparency Market Research
PR Newswire Europe - Tue Sep 06, 8:31AM CDT
ALBANY, New York, September 6, 2016 /PRNewswire/ --
PFE: 34.77 (unch), NVS: 80.15 (+0.77)
Pfizer Inc. Stock Presents A Huge Opportunity For Income Investors
Jack Foley - Amigobulls - Tue Sep 06, 3:37AM CDT
Income investors can benefit from the range bound trading action of Pfizer Inc. (NYSE FE) stock. Read more to find out how?
PFE: 34.77 (unch)
Low taxes at dozens of firms in spotlight after Apple ruling
By BERNARD CONDON - AP - Tue Sep 06, 2:06AM CDT
NEW YORK (AP) — It turns out some wealthy companies are just like some wealthy hedge fund managers: They're taxed at far lower rates than nearly everyone else.
EBAY: 32.41 (+0.13), PFE: 34.77 (unch)
Dow 30 Stock Roundup: EC Asks Apple to Pay $14.5B, Cisco to Buy Software Management Startup, ContainerX
Swarup Gupta - Zacks Investment Research - Fri Sep 02, 10:28AM CDT
The Dow swung between gains and losses over the week even as investors waited for further indications about the timing of a rate hikes.
PSXP: 49.69 (+0.08), GE: 31.05 (-0.24), PFE: 34.77 (unch), XOM: 88.57 (+1.15), DIS: 93.80 (-0.62), PG: 88.64 (+0.44), CVX: 102.43 (+1.50), AAPL: 107.70 (-0.03), VZ: 53.51 (+0.63), CSCO: 31.87 (+0.04)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Medivation, Inc.
BusinessWire - Fri Sep 02, 10:10AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medivation, Inc. ("Medivation" or "the Company" (Nasdaq: MDVN) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer" .
MDVN: 80.84 (-0.01), PFE: 34.77 (unch)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
BusinessWire - Thu Sep 01, 9:00AM CDT
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and Chief Executive Officer, at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016 at 12:15 p.m. Eastern Daylight Time.
PFE: 34.77 (unch), WFC: 49.99 (-0.56)
Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.75 (+0.43), PFE: 34.77 (unch), AMGN: 170.84 (+1.07), NVS: 80.15 (+0.77)
Pfizer's Lung Cancer Drug Xalkori Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:42AM CDT
Pfizer, Inc. (PFE) announced that its lung cancer drug Xalkori has been approved for an additional indication by the European Commission (EC).
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), PFE: 34.77 (unch)
ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:24AM CDT
ARIAD Pharmaceuticals (ARIA) completed the rolling submission of the new drug application for brigatinib, to the FDA.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), PFE: 34.77 (unch), ARIA: 10.41 (+0.29)
Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:59AM CDT
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
PFE: 34.77 (unch), AMGN: 170.84 (+1.07), NVS: 80.15 (+0.77)
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
BusinessWire - Wed Aug 31, 6:00AM CDT
Pfizer Inc. (NYSE FE) today announced that the European Commission has approved XALKORI(R) (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC). In the European Union (EU), XALKORI is also indicated for treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced NSCLC. In March of this year, XALKORI was approved by the United States (U.S.) Food and Drug Administration for patients with metastatic NSCLC whose tumors are ROS1-positive. With this approval, XALKORI becomes the only biomarker-driven therapy approved for patients with either ALK positive or ROS1-positive advanced NSCLC in the EU and U.S.
PFE: 34.77 (unch)
Novartis wins US OK for biosimilar version of Amgen's Enbrel
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Tue Aug 30, 5:29PM CDT
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
JNJ: 119.75 (+0.43), PFE: 34.77 (unch), AMGN: 170.84 (+1.07)
Why Pfizer Inc Stock Looks Set For A Good Run In 2016
Sangara Narayanan - Amigobulls - Sat Aug 27, 3:07AM CDT
Pfizer Inc (NYSE FE) has shown some encouraging signs in the first half of the year. Here's why the Pfizer stock looks poised for a good year ahead.
PFE: 34.77 (unch)
Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Swarup Gupta - Zacks Investment Research - Fri Aug 26, 8:24AM CDT
The Dow suffered losses over the week, weighed down by a number of factors.
MDVN: 80.84 (-0.01), JNJ: 119.75 (+0.43), GE: 31.05 (-0.24), GS: 169.33 (+0.15), PFE: 34.77 (unch), AZN: 33.09 (-0.22), MYL: 40.40 (+0.43), BWXT: 39.22 (-0.08), BA: 132.99 (+1.83), VZ: 53.51 (+0.63), MS: 31.75 (-0.14)
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
BusinessWire - Thu Aug 25, 9:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Medivation, Inc. (NASDAQ: MDVN) ("Medivation" or the "Company" relating to the proposed buyout of Medivation by Pfizer Inc.
MDVN: 80.84 (-0.01), PFE: 34.77 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders
BusinessWire - Thu Aug 25, 1:50PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
MDVN: 80.84 (-0.01), PFE: 34.77 (unch)
MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Medivation, Inc. (MDVN) Over the Proposed Sale of the Company to Pfizer Inc.
PR Newswire - Tue Sep 06, 3:49PM CDT
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medivation, Inc. ("Medivation" or the "Company"
(NasdaqGS:MDVN) for potential breaches of fiduciary duties in connection with the sale of the Company to Pfizer Inc. for approximately $14 billion. MDVN: 80.84 (-0.01), PFE: 34.77 (unch)
Watch for Shares of Pfizer (PFE) to Approach Resistance at $34.97
Comtex SmarTrend(R) - Tue Sep 06, 9:08AM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $34.74 today and have reached the first resistance level of $34.87. Investors may be interested in a cross of the next upside pivot targets of $34.97 and $35.20. PFE: 34.77 (unch)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Morgan Stanley Global Healthcare Conference
BusinessWire - Tue Sep 06, 9:00AM CDT
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 3:30 p.m. Eastern Daylight Time.
PFE: 34.77 (unch), MS: 31.75 (-0.14)
Pharmaceutical Products and CMO Market is Expanding at a CAGR 11.6% by 2024; Improving Regulatory Scenario Across Latin America Market: Transparency Market Research
PR Newswire Europe - Tue Sep 06, 8:31AM CDT
ALBANY, New York, September 6, 2016 /PRNewswire/ --
PFE: 34.77 (unch), NVS: 80.15 (+0.77)
Pfizer Inc. Stock Presents A Huge Opportunity For Income Investors
Jack Foley - Amigobulls - Tue Sep 06, 3:37AM CDT
Income investors can benefit from the range bound trading action of Pfizer Inc. (NYSE
FE) stock. Read more to find out how? PFE: 34.77 (unch)
Low taxes at dozens of firms in spotlight after Apple ruling
By BERNARD CONDON - AP - Tue Sep 06, 2:06AM CDT
NEW YORK (AP) — It turns out some wealthy companies are just like some wealthy hedge fund managers: They're taxed at far lower rates than nearly everyone else.
EBAY: 32.41 (+0.13), PFE: 34.77 (unch)
Dow 30 Stock Roundup: EC Asks Apple to Pay $14.5B, Cisco to Buy Software Management Startup, ContainerX
Swarup Gupta - Zacks Investment Research - Fri Sep 02, 10:28AM CDT
The Dow swung between gains and losses over the week even as investors waited for further indications about the timing of a rate hikes.
PSXP: 49.69 (+0.08), GE: 31.05 (-0.24), PFE: 34.77 (unch), XOM: 88.57 (+1.15), DIS: 93.80 (-0.62), PG: 88.64 (+0.44), CVX: 102.43 (+1.50), AAPL: 107.70 (-0.03), VZ: 53.51 (+0.63), CSCO: 31.87 (+0.04)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Medivation, Inc.
BusinessWire - Fri Sep 02, 10:10AM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medivation, Inc. ("Medivation" or "the Company"
(Nasdaq: MDVN) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer" . MDVN: 80.84 (-0.01), PFE: 34.77 (unch)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
BusinessWire - Thu Sep 01, 9:00AM CDT
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and Chief Executive Officer, at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016 at 12:15 p.m. Eastern Daylight Time.
PFE: 34.77 (unch), WFC: 49.99 (-0.56)
Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgen's Enbrel
ACCESSWIRE - Thu Sep 01, 8:15AM CDT
LONDON, UK / ACCESSWIRE / September 1, 2016 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS). On August 30, 2016, the US Food and Drug Administration (FDA) approved Novartis AG's drug Erelzi which is a biosimilar to Amgen Inc.'s (NASDAQ: AMGN) Enbrel. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
JNJ: 119.75 (+0.43), PFE: 34.77 (unch), AMGN: 170.84 (+1.07), NVS: 80.15 (+0.77)
Pfizer's Lung Cancer Drug Xalkori Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:42AM CDT
Pfizer, Inc. (PFE) announced that its lung cancer drug Xalkori has been approved for an additional indication by the European Commission (EC).
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), PFE: 34.77 (unch)
ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:24AM CDT
ARIAD Pharmaceuticals (ARIA) completed the rolling submission of the new drug application for brigatinib, to the FDA.
ANIP: 61.55 (+1.69), GERN: 3.02 (+0.27), PFE: 34.77 (unch), ARIA: 10.41 (+0.29)
Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:59AM CDT
Novartis (NVS) received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen???s blockbuster drug Enbrel (etanercept).
PFE: 34.77 (unch), AMGN: 170.84 (+1.07), NVS: 80.15 (+0.77)
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
BusinessWire - Wed Aug 31, 6:00AM CDT
Pfizer Inc. (NYSE
FE) today announced that the European Commission has approved XALKORI(R) (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC). In the European Union (EU), XALKORI is also indicated for treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced NSCLC. In March of this year, XALKORI was approved by the United States (U.S.) Food and Drug Administration for patients with metastatic NSCLC whose tumors are ROS1-positive. With this approval, XALKORI becomes the only biomarker-driven therapy approved for patients with either ALK positive or ROS1-positive advanced NSCLC in the EU and U.S. PFE: 34.77 (unch)
Novartis wins US OK for biosimilar version of Amgen's Enbrel
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Tue Aug 30, 5:29PM CDT
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
JNJ: 119.75 (+0.43), PFE: 34.77 (unch), AMGN: 170.84 (+1.07)
Why Pfizer Inc Stock Looks Set For A Good Run In 2016
Sangara Narayanan - Amigobulls - Sat Aug 27, 3:07AM CDT
Pfizer Inc (NYSE
FE) has shown some encouraging signs in the first half of the year. Here's why the Pfizer stock looks poised for a good year ahead. PFE: 34.77 (unch)
Dow 30 Stock Roundup: Pfizer's Big Buy, Boeing's Big Win
Swarup Gupta - Zacks Investment Research - Fri Aug 26, 8:24AM CDT
The Dow suffered losses over the week, weighed down by a number of factors.
MDVN: 80.84 (-0.01), JNJ: 119.75 (+0.43), GE: 31.05 (-0.24), GS: 169.33 (+0.15), PFE: 34.77 (unch), AZN: 33.09 (-0.22), MYL: 40.40 (+0.43), BWXT: 39.22 (-0.08), BA: 132.99 (+1.83), VZ: 53.51 (+0.63), MS: 31.75 (-0.14)
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
BusinessWire - Thu Aug 25, 9:00PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Medivation, Inc. (NASDAQ: MDVN) ("Medivation" or the "Company"
relating to the proposed buyout of Medivation by Pfizer Inc. MDVN: 80.84 (-0.01), PFE: 34.77 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders
BusinessWire - Thu Aug 25, 1:50PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
MDVN: 80.84 (-0.01), PFE: 34.77 (unch)
(0)
(0)Scroll down for more posts ▼